About PERFUSION MEDICAL LLC
Perfusion Medical is a biotechnology company developing PM-208, an IV therapeutic for hemorrhagic shock and ischemic conditions, with funding from the Department of Defense. The drug aims to improve survival rates and tissue perfusion in trauma and critical care settings.
Development of PM-208, an IV therapeutic for hemorrhagic shock and ischemic conditionsImprovement of tissue perfusion and oxygen delivery in oxygen-starved tissuesPotential for 3x survival improvements in trauma and ischemiaApplications in military and civilian trauma care, including austere environments
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| POLYETHYLENE GLYCOL-20K/8K: A PATENTED INTRAVENOUS SOLUTION TO ACUTE KIDNEY INJURY | Department of Defense | $75K | |
| DHA SBIR DIRECT TO PHASE II MEDICAL R&D CONTRACT FROM PROPOSAL NO. H2D-0122 FOR "IND-ENABLING STUDIES OF PM-20 | Department of Defense | $3.0M | |
| HUMAN CLINICAL TRIAL FOR SAFETY OF PM-208 ANTI-SHOCK DRUG | Department of Defense | $1.8M | |
| RESEARCH AND DEVELOPMENT OF OPTIMAL DOSING AND FORMULATION OF PM-208 (PEG-20K/8K) FOR AF FIELD USE | Department of Defense | $1.8M | |
| IND-ENABLING STUDIES OF PM-208: A NOVEL PRE-HOSPITAL ANTI-SHOCK THERAPEUTIC | Department of Defense | $1.5M |
Is this your company?
Claim PERFUSION MEDICAL LLC to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim PERFUSION MEDICAL LLC & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.